HLB Pharmaceutical Co., Ltd (047920.KQ)
KRW 20500.0
(2.5%)
KRW 20500.0
(2.5%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 581.09 Million KRW | -535.12% |
| 2022 | -1.39 Billion KRW | -159.71% |
| 2021 | 8.28 Billion KRW | 48.56% |
| 2020 | -77.76 Billion KRW | 30.54% |
| 2019 | 2.13 Billion KRW | 141.81% |
| 2018 | -3.71 Billion KRW | -60.41% |
| 2017 | -2.4 Billion KRW | -320.83% |
| 2016 | 1.4 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 2.52 Billion KRW | -99.63% |
| 2024 Q2 | 1.84 Billion KRW | 9366.06% |
| 2023 Q3 | -6.29 Billion KRW | 16.5% |
| 2023 FY | - KRW | -535.12% |
| 2023 Q4 | -2.96 Billion KRW | 52.9% |
| 2023 Q2 | -7.53 Billion KRW | -515.12% |
| 2023 Q1 | 1.81 Billion KRW | 265.72% |
| 2022 FY | - KRW | -159.71% |
| 2022 Q1 | -1 Billion KRW | -793.27% |
| 2022 Q4 | -1.09 Billion KRW | -60.28% |
| 2022 Q3 | -683.81 Million KRW | -184.1% |
| 2022 Q2 | 813.06 Million KRW | 181.0% |
| 2021 Q3 | 2.12 Billion KRW | 0.0% |
| 2021 FY | - KRW | 48.56% |
| 2021 Q4 | 144.78 Million KRW | -93.19% |
| 2020 FY | - KRW | 30.54% |
| 2019 FY | - KRW | 141.81% |
| 2018 FY | - KRW | -60.41% |
| 2017 FY | - KRW | -320.83% |
| 2016 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| CMG Pharmaceutical Co., Ltd. | 5.59 Billion KRW | 89.613% |
| Celltrion Pharm, Inc. | 54.22 Billion KRW | 98.928% |
| Huons Global Co., Ltd. | 151.92 Billion KRW | 99.618% |
| DongKook Pharmaceutical Co., Ltd. | 88.68 Billion KRW | 99.345% |
| Enzychem Lifesciences Corporation | -5.77 Billion KRW | 110.064% |
| Humedix Co., Ltd. | 54.87 Billion KRW | 98.941% |
| Boditech Med Inc. | 36.48 Billion KRW | 98.407% |
| EuBiologics Co., Ltd. | -4.39 Billion KRW | 113.231% |
| FutureChem Co.,Ltd | -591.25 Million KRW | 198.281% |
| Huons Co., Ltd. | 74.23 Billion KRW | 99.217% |
| BNC Korea Co., Ltd. | 14.17 Billion KRW | 95.9% |
| AptaBio Therapeutics Inc. | -13 Billion KRW | 104.468% |